{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[5, 83]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['83']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Red blood cells count decreased",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['50']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['50']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['50']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Leukopenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['67']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Neutropenia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['50']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "AST increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "AST increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 100]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['100']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[4, 67]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['67']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "ALT increase",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "ALT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 75]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['75']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "GGT increase",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['33']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hypocalcemia",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['17']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Hyponatremia",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Nausea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[3, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['50']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 50]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['50']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Nausea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Vomiting",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['33']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Vomiting",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['25']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['33']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 1",
                    "dose": "<100 mg",
                    "number of patients": "6",
                    "adverse event": "Diarrhea",
                    "grade": "G3"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[2, 33]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['33']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G1"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Red blood cells count decreased",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Leukopenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Neutropenia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "AST increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['4']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "ALT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "GGT increase",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hypocalcemia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Hyponatremia",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['3']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Nausea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Vomiting",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 2",
                    "Sample Size": "4",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['1']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 incidence']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G1 count']",
                "outcomes": "['0']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G2 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "dasatinib",
                    "adverse event classification": "NCI-CTCAE v4.03",
                    "dose level": "Level 2",
                    "dose": "100 mg",
                    "number of patients": "4",
                    "adverse event": "Diarrhea",
                    "grade": "G2"
                },
                "measures": "[number of patients, percentage]",
                "outcomes": "[1, 25]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "AE": "Diarrhea",
                    "Treatment": "Dasatinib",
                    "Dose Level": "Level 1",
                    "Sample Size": "6",
                    "Grading System": "NCI-CTCAE v4.03"
                },
                "measures": "['G3 count']",
                "outcomes": "['2']"
            },
            "match": "no"
        }
    ],
    "total_extracted_claims": 35,
    "total_ground_truth_claims": 126,
    "number_of_matches": 33
}